FDA approves first blood test to detect gene mutation associated with non-small cell lung cancer

June 1, 2016 -- The U.S. Food and Drug Administration today approved the cobas EGFR Mutation Test v2, a blood-based companion diagnostic for the cancer drug Tarceva (erlotinib). This is the first FDA-approved, blood-based genetic test that can...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news